NCT00934921View on ClinicalTrials.gov

Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

February 28, 2003

Study Completion Date

February 28, 2003

Conditions
Healthy
Interventions
DRUG

Ondansetron

1 x 8 mg Orally Disintegrating Tablet

DRUG

Zofran®

1 x 8 mg ODT

Trial Locations (1)

77042

Novum Pharmaceutical Research Services, Houston

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT00934921 - Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions | Biotech Hunter | Biotech Hunter